RNLX Renalytix AI plc Stock Quote

RNLX [NASD]

Healthcare | Diagnostics & Research | United Kingdom

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	34.92M	Perf Week	46.36%
Market Cap	860.66M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	5.50M	Perf Month	77.57%
Income	-	PEG	-	EPS next Q	-	Inst Own	13.60%	Short Float	1.76%	Perf Quarter	97.52%
Sales	-	P/S	-	EPS this Y	72.30%	Inst Trans	-	Short Ratio	1.45	Perf Half Y	65.33%
Book/sh	2.55	P/B	8.75	EPS next Y	-	ROA	-	Target Price	-	Perf Year	-
Cash/sh	2.13	P/C	10.46	EPS next 5Y	-	ROE	-	52W Range	9.91 - 22.48	Perf YTD	39.50%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-0.71%	Beta	-
Dividend %	-	Quick Ratio	22.70	Sales past 5Y	-	Gross Margin	-	52W Low	125.30%	ATR	1.60
Employees	17	Current Ratio	22.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	80.19	Volatility	15.61% 9.78%
Optionable	No	Debt/Eq	0.02	EPS Q/Q	81.90%	Profit Margin	-	Rel Volume	1.88	Prev Close	22.32
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	66.71K	Price	22.32
Recom	-	SMA20	44.66%	SMA50	64.82%	SMA200	64.18%	Volume	125,722	Change	0.00%

Aug-11-20

Initiated

Stifel

Buy

Jan-13-21 02:00AM	Renalytix Commends HHS/CMS on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics GlobeNewswire +18.77%
Jan-06-21 08:54AM	Renalytix AI (RNLX) Catches Eye: Stock Jumps 7% Zacks
07:30AM	The Daily Biotech Pulse: Aerpio Reviews Strategic Options, Hologic Goes Shopping Benzinga
Jan-05-21 06:00AM	Early Risk Identification at Core of Innovative Kidney Care Partnership Between Renalytix, DaVita GlobeNewswire +6.89%
Jan-04-21 08:05AM	RenalytixAI to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Nov-29-20 11:42AM	Do Hedge Funds Love Renalytix AI plc (RNLX)? Insider Monkey
Nov-25-20 07:30AM	Kantaro Receives FDA Emergency Use Authorization for Semi-Quantitative COVID-19 Antibody Test Kit that Detects the Presence and Level of SARS-CoV-2 IgG Antibodies PR Newswire +31.71%
07:00AM	RenalytixAI Reports Financial Results for First Quarter of Fiscal Year 2021 GlobeNewswire
Nov-13-20 02:00AM	RenalytixAI to Participate in the Stifel 2020 Healthcare Conference GlobeNewswire
Nov-06-20 07:00AM	Renalytix AI plc (RenalytixAI or the Company) Change of adviser GlobeNewswire
Nov-02-20 10:30AM	Posting of Annual Report & Accounts and Notice of AGM GlobeNewswire
Oct-28-20 07:30AM	EKF and Kantaro Partner to Market Quantitative COVID-19 Antibody Testing in the UK and Europe PR Newswire
Oct-27-20 03:00AM	Renalytix AI plc (RenalytixAI or the Company) Full Year Report GlobeNewswire
Oct-26-20 07:30AM	CE Mark Approval Granted to Kantaro COVID-SeroKlir and COVID-SeroIndex Quantitative Antibody Test Kits PR Newswire +6.19%
Sep-22-20 07:00AM	RenalytixAI Receives California Commercial Laboratory Certification GlobeNewswire
Sep-18-20 07:00AM	RenalytixAI Reaches Milestone of KidneyIntelX Commercial Testing with Mount Sinai Health System GlobeNewswire
Aug-26-20 07:00AM	RenalytixAI Files Submission Seeking U.S. FDA Clearance of KidneyIntelX GlobeNewswire
Aug-21-20 03:00AM	RenalytixAI to Collaborate with AstraZeneca to Improve Outcomes for Patients with Chronic Disease GlobeNewswire
Aug-03-20 08:00AM	KidneyIntelX in Multi-Center Study to Monitor and Predict Kidney Risk in COVID-19 Patients GlobeNewswire +7.33%
Jul-27-20 08:00AM	RenalytixAI Announces Over Allotment Option Exercise Raises an Additional US$10.9M GlobeNewswire +6.17%
Jul-21-20 03:57PM	RenalytixAI Announces Closing of Global Offering and Resulting Total Voting Rights GlobeNewswire
Jul-16-20 11:38PM	RenalytixAI Announces Pricing of Global Offering and Approval to List on the Nasdaq Global Market GlobeNewswire

Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience